Earnings Feed
Start Free
PHIBRO ANIMAL HEALTH CORP·4

Feb 18, 7:40 PM ET

BENDHEIM JACK 4

Research Summary

AI-generated summary

Updated

Phibro (PAHC) 10% Owner Jack Bendheim Sells Shares

What Happened Jack Bendheim, a director/officer and reported 10% owner (via BFI Co., LLC), sold a total of 14,080 Phibro Animal Health (PAHC) shares in open-market transactions on Feb 13 and Feb 18, 2026. The sales break down as: 7,040 shares at a weighted average price of $51.96 for $365,822; 6,824 shares at a weighted average price of $51.38 for $350,599; and 216 shares at a weighted average price of $51.97 for $11,225 — aggregate proceeds ≈ $727,646. These transactions were sales (not purchases), and at least some were effected under a Rule 10b5-1 trading plan.

Key Details

  • Dates and reported weighted-average prices:
    • 2026-02-13: 7,040 shares @ $51.96 (total $365,822). Price range reported: $51.90–$52.05 (footnote).
    • 2026-02-18: 6,824 shares @ $51.38 (total $350,599). Price range reported: $50.90–$51.875 (footnote).
    • 2026-02-18: 216 shares @ $51.97 (total $11,225). Price range reported: $51.61–$52.345 (footnote).
  • Aggregate sold: 14,080 shares for ≈ $727,646.
  • Ownership after transaction: not specified in the filing (filing does not state total shares held post-sale).
  • Notable footnotes:
    • Sales were effected pursuant to a Rule 10b5-1 plan adopted by BFI Co., LLC (May 30, 2025).
    • Some reported securities are directly held by BFI; Jack Bendheim exercises voting/dispositive power over BFI and disclaims beneficial ownership except to his pecuniary interest. At least some shares are directly held by Mr. Bendheim.
    • Reported prices are weighted averages; the filing offers to provide a breakdown of the number of shares sold at each separate price on request.
  • Filing timeliness: report filed Feb 18, 2026 covering trades on Feb 13 and Feb 18; the filing itself does not mark a late report.

Context

  • These are routine sales by a significant owner and include transactions executed under a pre-established 10b5-1 plan, which typically schedules sales in advance and can reduce signals about timing or intent. For retail investors, purchases by insiders tend to be more informative than sales; these sales alone do not indicate company fundamentals.